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Abstract  
Several studies have highlighted cancer metabolism as a suitable target to 
develop new therapies. This thesis aimed at determining the role of lactate 
metabolism in AML, both VEGF dependent and independent, by developing an in vitro 
study (pro-myelocytic-HL60 and erithroblastic-HEL). 
 We observed that HL60 and HEL have different metabolic profiles when 
exposed to lactate and/or VEGF. NMR analysis showed that HL60 uses lactate to 
synthetize acetate, amino acids and malate and upon VEGF stimulation nucleotides are 
detected though not originated from lactate or glucose. Concordantly, VEGF exposure 
increases the expression of MCT1 in HL60 cells. HEL cells’ metabolic profile is not 
altered by VEGF stimulation and lactate is mainly converted into malate and proline. 
However, VEGF decreases MCT1 and MCT4 levels in HEL. In both cell lines, LDHA and 
LDHB expression levels are equivalent between conditions. Concerning VEGF 
receptors, in HL60 VEGF increases and lactate decreases the levels of KDR, expressing 
more FLT1. HEL cells barely express KDR and all the stimulations tested increase the 
expression of FLT1.  
Cell cycle analysis showed that VEGF and lactate increase proliferation of 
respectively HL60 and HEL cells. The percentage of dead cells in the same conditions 
was higher, assenting the concomitant media consumption. 
 In order to validate our results, we verified that the majority of BM samples 
express higher levels of MCT1 than MCT4. By immunohistochemistry, MCT1 is 
expressed in aberrant and large cells whereas MCT4 is expressed in normal mature and 
progenitor cells. MCT1 positive cells are preferentially localised in paratrabecular 
regions, the VEGF rich niches. 
 Our study showed VEGF regulates lactate metabolism and proliferation in 
monocytic AML cells. In human samples, higher levels of MCT1 are expressed at 
diagnosis and relapse, being MCT1 expressed in cells morphologically aberrant. Taking 
together out results indicate MCT1 as a suitable therapeutic target in AML. 
 
Key words: VEGF, lactate, metabolism, cancer, leukaemia, metabolic symbiosis   
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Resumo  
Cancro define um vasto grupo de neoplasias malignas que resultam de várias 
alterações dos mecanismos fisiológicos que regulam os vários processos celulares. O 
processo de carcinogénese conduz à aquisição de uma série de características onde se 
incluem o aumento da taxa de proliferação, sobrevivência e resistência à morte 
celular. A causa final da morte da maioria dos doentes com cancro é o 
desenvolvimento de metástases [1], que se formam a partir da capacidade que as 
células cancerígenas têm de se separar do tumor primário, migrar, invadir e colonizar 
outros órgãos. 
O conhecimento da biologia do cancro tem vindo a crescer exponencialmente 
nas últimas duas décadas. A carcinogénese é um processo de várias etapas que 
reflecte alterações genéticas que levam à transformação progressiva de células 
normais em células malignas [2]. Hanahan e Weinberg [3], propõem que, durante o 
processo de carcinogénese, as células têm de adquirir seis características biológicas 
principais: sustentar a capacidade proliferativa; evadir-se aos sinais de supressores de 
crescimento; resistir à morte celular; adquirir uma capacidade replicativa infinita; 
induzir angiogénese, e desencadear o processo de invasão e metastização. Mais 
recentemente, os mesmos autores revelaram mais duas novas características: a 
capacidade de escapar ao controlo do sistema imunitário, e a capacidade de adaptação 
do metabolismo energético.  
A leucemia mielóide aguda (LMA) é uma doença clonal geneticamente 
heterogénea caracterizada pela acumulação de alterações genéticas somáticas em 
células progenitoras hematopoiéticas que levam à alteração dos mecanismos normais 
de auto-renovação, proliferação e diferenciação destas células [4]. Estas alterações 
levam a uma perda da função hematopoiética normal que pode resultar em 
insuficiência da função dos glóbulos brancos e vermelhos, bem como as plaquetas e 
que, quando não tratada, geralmente leva à morte do doente em semanas ou meses 
após do seu diagnóstico [5, 6]. 
Hanahan e Weinberg [3] identificaram a reprogramação do metabolismo 
energético como uma das marcas biológicas emergentes das células cancerígenas. A 
proliferação de células cancerígenas apresenta exigências metabólicas diferentes em 
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comparação com a maioria das células diferenciadas normais [7]. De forma a 
responder às necessidades de uma elevada taxa de proliferação, as células 
cancerígenas consomem mais nutrientes para suprir as vias de síntese de 
macromoléculas. As vias metabólicas devem assim ser reprogramadas de forma a 
equilibrar os processos biossintéticos com a produção de ATP necessária para suportar 
o crescimento e sobrevivência celular [8].  
Em alguns tumores, a taxa de glicólise é normalmente mais elevada do que nos 
tecidos normais, principalmente para sustentar a replicação do DNA através da via das 
fosfatos de pentose (PPP), em detrimento da obtenção do máximo de ATP a partir da 
glucose [9]. A manutenção desta taxa de glicólise requer elevadas quantidades de 
dinucleótido de nicotinamida e adenina (NAD+), que é eficientemente produzido na 
conversão de piruvato em lactato, promovendo a auto-suficiência da glicólise que 
passa a depender apenas da capacidade celular de captação de glucose [10].  
Os elevados níveis de lactato resultante da glicólise têm sido correlacionados 
com o aumento de metástases, reincidência do tumor e mau prognóstico. O 
metabolismo (anabolismo e catabolismo) do lactato assenta da acção de enzimas 
desidrogenases de lactato (LDHs) e dos transportadores de monocarboxilados (MCTs).  
As LDHs compreendem um grupo de cinco isoenzimas tetraméricas que 
resultam da combinação de duas subunidades A e B. De acordo com a sua composição 
estas enzimas podem catalisar a conversão de piruvato em lactato ou o contrário com 
interconversão de NADH e NAD+ [11, 12]. Em muitos tumores, principalmente nos 
altamente glicolíticos, encontram-se níveis mais elevados de expressão de LDHA do 
que em tecidos normais, o que está relacionado com o mau prognóstico da doença 
[13, 14]. A LDHB esta ligada ao crescimento do tumor em cancro de mama de células 
basais e está presente em tumores com potencial metastático mais elevado [15, 16]. 
Os MCTs constituem uma família de 14 transportadores codificados pela família 
de genes de transportadores de monocarboxilados (SLC16) evolutivamente 
conservada, e têm como função transportar uma única molécula carboxilada através 
da membrana. Até hoje apenas quatro dos MCTs (MCT1-4) foram caracterizados como 
facilitadores de transporte de piruvato e lactato sendo cruciais para a homeostasia do 
lactato [17, 18]. No contexto do cancro, o MCT1 (importação de lactato) e o MCT4 
(exportação de lactato) são os dois principais MCTs encontrados em células tumorais 
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sendo que elevados níveis destes transportadores estão relacionados com um mau 
prognóstico. 
Um tumor apresenta um gradiente de O2 dependente da distância a que se 
encontra dos vasos sanguíneos funcionais. As células tumorais mais próximas de um 
vaso sanguíneo têm mais oxigénio disponível enquanto as mais afastadas têm menos, 
estando portanto em hipoxia. Estas últimas células vão ter níveis mais elevados do 
factor indutível pela hipoxia (HIF-1) que vai leva ao aumento do consumo de glucose e, 
consequentemente, ao aumento da sua conversão em piruvato que é então 
convertido em lactato por LDHA. Este lactato produzido pelas células em hipoxia é 
exportado pelo MCT4. Sonveaux et al (2008) [19] descreveu que as células tumorais 
aeróbicas, mais próximas dos vasos, expressam mais MCT1 e importam o lactato que é 
usado como fonte de carbono e energia através da acção da LDHB. Estas células 
consomem então lactato em detrimento da glucose que fica então disponível para ser 
consumida pelas células tumorais em hipoxia [19, 20]. 
Para além do seu papel na angiogénese, o factor de crescimento VEGF também 
tem sido descrito como um factor de sobrevivência para as células cancerígenas, 
incluindo LMA [21]. A desregulação da produção de VEGF tem um impacto significativo 
sobre o desenvolvimento de leucemia e constitui um passo importante para a 
progressão em LMA [22]. Está descrito que, por via parácrina, as células de LMA 
aumentam a produção de VEGF o que leva a que as células endoteliais presentes na 
medula óssea a segregar vários factores de crescimento e citoquinas que estimulam o 
crescimento de células LMA [23, 24].  
No presente trabalho pretende-se determinar o papel do metabolismo do 
lactato, dependente ou não de um estímulo de VEGF, em LMA. Para isso foram usadas 
duas linhagens de LMA diferentes, uma pro-mieloblástica (HL60) e outra eritroblástica 
(HEL) e amostras de doentes com LMA.  
Os resultados obtidos por ressonância magnética nuclear (NMR) demonstram 
que em HL60 os carbonos do lactato são incorporados na síntese de acetato, 
aminoácidos e malato independentemente da presença de VEGF e que quando este 
está presente a glucose não é detectada nos extractos celulares. Nas HEL a 
estimulação com VEGF não produz qualquer modificação visível no seu perfil 
metabólico, sendo que o lactato é convertido maioritariamente em malato e prolina. 
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Em condições normais, as HL60 importa mais 13C-lactato que as células HEL, quando 
estimulamos as células com VEGF os níveis de incorporação de lactato pelas células 
HL60 descem para níveis semelhantes às HEL controlo. 
Brito (2011) [25] observou que as células HL60 quando estimuladas com VEGF 
expressam mais MCT1 enquanto a estimulação com lactato e/ou VEGF nas HEL diminui 
a expressão de MCT1. A expressão de MCT4 em ambas as linhas só parece ser afectada 
pela presença de lactato e VEGF. A expressão de LDHA e B em células HL60 e HEL não 
parece ser afectada pela estimulação com lactato e/ou VEGF. Relativamente à 
expressão dos receptores de VEGF (FLT1 e KDR) em células HL60 observa-se que a 
estimulação com lactato e VEGF leva a um aumento de expressão de FLT1 e que em 
células HEL todas as estimulações levam a um aumento da expressão de FLT1. Em 
ambas as linhas celulares temos uma aparente deslocalização do VEGF para o núcleo 
quando estimuladas com lactato e VEGF sendo que nas células HEL esta observação é 
feita também no controlo e na estimulação com VEGF. A expressão do KDR em células 
HL60 parece aumentar quando as células são tratadas com VEGF e diminuir quando 
expostas a lactato com e sem VEGF. 
Através da análise do ciclo celular por FACS vemos que as células HL60 
apresentam um menor tempo acumulado de duração do ciclo celular quando são 
estimuladas com VEGF, enquanto nas células HEL o mesmo acontece na presença de 
lactato. O ensaio de morte celular vem de encontro a estas observações uma vez que 
temos um aumento das células necróticas quando as células são expostas a VEGF. 
Em simultâneo explorámos o papel de FOXM1 na regulação da expressão de 
MCT1, com base trabalho realizados pelo nosso grupo em outros modelos de cancro. 
Contudo, neste modelo in vitro de LMA, o FOXM1 não parece ser um activador da 
expressão de MCT1. 
Em amostras de medula óssea de doentes com LMA foi possível verificar que a 
maioria dos doentes expressam níveis mais elevados de MCT1 do que MCT4 ao nível 
do RNA. Doentes com recidiva da doença, apresentam um aumento da expressão 
relativa de MCT1. A análise por imuno-histoquímica revela que MCT1 e MCT4 são 
expressos em células diferentes, o MCT1 é expresso em células grandes e com 
morfologia aberrante (blastos leucémicos) e o MCT4 é expresso em células maduras de 
várias linhagens e células progenitoras normais. As células MCT1 positivas têm 
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tendência para uma disposição para-trabecular (junto às trabéculas ósseas) enquanto 
as MCT4 positivas encontram-se difusamente distribuídas. O que está de acordo com a 
descrição dos nichos de blastos leucémicos na medula óssea que se encontram nas 
zonas ricas em VEGF próximas do osso [26]. 
Em conjunto, estes resultados demonstram que VEGF influencia a proliferação 
e o metabolismo de células de LMA de linhagem monocítica influenciando a expressão 
de intervenientes no metabolismo do lactato. O MCT1 é um elemento crucial no 
metabolismo de lactato e está expresso em células leucémicas de doentes com LMA. 
Assim, o MCT1 poderá constituir um novo alvo terapêutico em doentes com LMA.  
 
Palavras-chave: VEGF, lactate, metabolismo, cancro, leucemia, simbiose metabólica  
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Introduction 
 
1. Cancer 
Cancer comprises a group of malignant neoplasias, arising from multiple 
alterations in the physiological mechanism of normal cells. These alterations lead cells 
to a state characterized, in part, by a higher proliferation rate, survival and resistance 
to apoptosis. The cause of death of most cancer patients is the development of 
metastases [1] which emerge from the ability of cancer cells to detach from the 
primary tumour, disseminate, invade and colonize other organs. 
In economically developed countries, cancer is the leading cause of death [27]. 
Adoption of cancer-associated lifestyle choices such as smoking, physical inactivity, 
synthetic and high fat diets and population aging is increasing the burden of cancer in 
developing countries, cancer being the second leading cause of death. In Europe, in 
2012 there were 3.45 million new cases of cancer (excluding non-melanoma skin 
cancers), 53% occurring in men and 47% in women, accounting for approximately 
707,000 men and 555,000 women dying from cancer [28]. 
 
2. Cancer biology and Cancer microenvironment 
Carcinogenesis is a stepwise process, whose stages are underlied by genetic 
alterations, driving the transformation from normal into malignant cells [2, 29]. The 
huge variety cancer types  is defined by several features, also named “hallmarks”, that 
collectively define cancer: self-sufficiency in growth signals, insensitivity to antigrowth 
signals, evasion of cell death, increased replicative potential, sustained angiogenesis, 
and tissue invasion and metastasis [2, 3].  
Evading immune system and reprogrammed metabolism were also considered 
emerging hallmarks of cancer [3]. In fact, regarding the evasion from immune system, 
solid tumours seem to avoid the recognition and elimination the majority of cancer 
cells by the immune system [3]. Other evidence revealed that cancer cells are able to 
reprogram their carbon and energy metabolism, being the most explored the increase 
rate of glycolysis even in aerobiosis [3, 30]. Although this metabolic switch represents 
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a disadvantage in energetic terms, increased glycolysis allows the diversion of 
glycolytic intermediates into various biosynthetic pathways, including those generating 
nucleosides and amino acids, facilitating the synthesis of biomass to sustain cell 
proliferation [3, 7]. 
All these characteristics of cancer result from a dynamic interaction between 
tumour cells and their microenvironment. The development of a tumour occurs in a 
complex network, characterized by the presence of extracellular matrix (ECM), 
epithelial and mesenchymal cells, vascular and lymphatic vessels, inflammatory and 
immune cells. Cancer cells interact with surrounding environment taking advantage of 
inorganic and organic compounds and signalling effectors.  In carcinogenesis the 
behaviour of a cell is mostly determined by its interaction with the microenvironment 
[31]. Thus in the clinical setting, targeting tumour microenvironment in order to affect 
cancer cells has become mandatory [32]. 
In fact, for a long time only neoplastic cells were the focus of interest in cancer 
research, being stroma considered just a reactive component [33]. Research on the 
underlying mechanisms of cancer has finally pointed out the relevance of tumoral 
stroma [33–36]. This is now considered an integral part of a neoplasm, perceiving as a 
complex tissue composed of several distinct cell types that participate in heterotypic 
interactions, creating the concept of tumour microenvironment (reviewed in [3]).  
Besides the paracrine mode of action of growth factors that dominates 
physiological processes, many tumour cells pathophysiologically acquire the ability to 
produce growth factors to auto-regulated their proliferation – autocrine stimulation  
[37, 38]. Alongside such autocrine loops, other mechanisms may also lead to 
constitutive pathways activation in tumours, whereas specific mutations can elicit 
ligand-independent signalling, enabling cancer cells to become hyper-responsive to 
growth factors [2, 39, 40]. The switch in ECM components in cancer stroma also 
favours the transmition of pro-growth signals, contributing to tumour self-sufficiency 
in terms of growth signals [41]. 
Loss of sensitivity to anti-growth signals constitutes the first hallmark of cancer 
by also leading to unsupervised growth [2]. Cell cycle involves multiple checkpoints 
that assess extracellular growth signals, cell size and DNA integrity, in which cyclin-
dependent kinases (CDKs) and cyclins act by inducing cell cycle progression, and CDKs 
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inhibitors (CKIs) act as negative regulators [42]. Deregulation of the cell cycle is one of 
the most frequent alterations during tumour development [43].  
Cancer cells must also evade anti-proliferative signals by turning off elements, 
as integrins and other adhesion molecules that send antigrowth signals, favouring 
instead pro-growth signals and by avoiding cell differentiation [2].  
The ability of tumour cell populations to expand in number is also determined 
by the resistance to cell death. The most common strategy to avoid apoptosis is a 
mutation involving the p53 tumour suppressor, resulting in the removal of a key 
component of the DNA damage sensor that can induce the apoptotic effector cascade 
[2, 44, 45]. 
The loss of capacity for senescence leads tumour cells almost to immortality, an 
essential feature for malignant growth state, achieved in most cases, from the 
increased expression of telomerase, an enzyme that maintains the telomeres at a 
length above a critical threshold, permitting cell division [2, 46, 47]. 
Tumour cells initially lack angiogenic ability [2, 48]. In order to expand in size, 
neoplasms must develop angiogenic ability, which is acquired during tumour 
development via an “angiogenic switch” [49]. That activation appears to occur by 
changing the balance of angiogenesis inducers and inhibitors [49]. This common shift 
usually involves altered gene transcription. Many tumours show increased expression 
of vascular endothelial growth factor (VEGF) and/or fibroblast growth factors (FGFs), 
compared to normal tissues. The downregulation of endogenous inhibitors, such as 
thrombospondin-1 or β-interferon is also frequent [3, 50]. 
After the ability of tumour to grow beyond the limitations of passive nutrient 
diffusion, conferred by ability to form blood vessels, primary tumours may release cells 
that are able to invade adjacent tissues and travel through bloodstream to distant 
organs, where they may form secondary tumours, so called metastases [51].  
 
3. Acute myeloid leukaemia  
Myeloid leukaemia, the most common group of haematological malignancies, is 
thought to derive from pluripotential or multipotential stem cells that give rise to a 
diverse range of neoplasias, some of them being characterised by specific genetic 
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abnormalities. Leukaemias are divided into two main categories based on the affected 
cell lineage, myeloid or lymphoid, and then sub-divided according to the cells’ 
maturation state, morphology, immunopositivity, genetic characteristics and clinical 
behaviour [52]. The most common subtypes of leukaemia are acute lymphocytic 
leukaemia, acute myeloid leukaemia, chronic lymphocytic leukaemia and chronic 
myeloid leukaemia where acute stands for a fast progression and chronic for a slow 
progression of the disease. 
In Europe, according to Fey and Dreyling (2009) [53], the incidence of acute 
myeloid leukaemia (AML) in adults is 5–8 cases/100000/year and the mortality is about 
4–6 cases/100000/year. AML is a genetically heterogeneous clonal disorder 
characterized by the accumulation of somatically acquired genetic alterations in 
hematopoietic progenitor cells that alter their normal mechanisms of self-renewal, 
proliferation and differentiation [4]. This malignant alteration leads to a loss of normal 
hematopoietic function that results in life threatening insufficiency of normal white 
and red blood cells as well as platelets, which, if left untreated, typically leads to death 
within weeks to months of its clinical presentation [5, 6]. According to World Health 
Organization (WHO), the term “myeloid” includes all cells belonging to the granulocytic 
(neutrophil, eosinophil, basophil), monocytic/macrophage, erythroid, megakaryocytic 
and mast cell lineages. AML can be divided in acute monoblastic/monocytic leukaemia, 
acute erythroid leukaemia, acute megakaryoblastic leukaemia, acute basophilic 
leukaemia and acute panmyelosis with myeloﬁbrosis (Figure 1) [54].  
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Figure 1 - WHO’s leukaemia classification, in particular myeloid acute leukaemia. Based on Vardiman 
et al, 2009 [54] 
Remission rates and overall survival depend on a number of features, including 
age of the patient, cytogenetic alterations and other molecular changes exhibited by 
malignant leukemic clones, previous bone marrow (BM) disorders and comorbid 
illnesses [5]. 
During leukaemogenesis the key oncogenic events that will lead to AML are 
often divided into class I and class II mutations. Mutations that confer a proliferation 
or survival advantage to blast cells but do not affect their differentiation, including 
mutations of FMS-like tyrosine kinase 3 (FLT3),   GTPase  (Ras) and Tyrosine-protein 
phosphatase non-receptor type 11 (PTPN11), and the breakpoint cluster region at 
chromosome 22/Abelson murine leukaemia viral oncogene homolog 1  (BCR/ABL) and 
ETS family transcription factor/platelet-derived growth factor  receptor (TEL/PDGFR) 
gene fusions are defined as Class I. Class II mutations correspond to gene mutations 
and translocation-associated fusions that impair differentiation and apoptosis and 
include the runt-related transcription factor 1/runt-related transcription factor 1 
translocated to 1 (cyclin D-related) (AML/ETO) and the  promyelocytic leukaemia gene/ 
retinoic acid receptor  (PML/RAR) fusions, the lysine (K)-specific methyltransferase 
2A (MLL) rearrangements, and mutations in the CCAAT/enhancer binding protein 
(CEBPA), the core-binding factor (CBF), the HOX family members, the CREB-binding 
protein/binding protein p300 (CBP/p300), and co-activators of the transcriptional 
intermediary factor 1 (TIF1) [55, 56]. Together these class I and class II mutations have 
a prognostic relevance that has led to the widespread adoption of risk stratification, 
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with patients divided into cytogenetically defined risk groups with significant 
differences in overall survival [57]. 
 
4. Cancer Metabolism 
Tumour cell metabolism was actively explored in the pre-genomics era, the 
discovery of tumour suppressor genes and oncogenes dampened interest in 
metabolism as a potential way to identified cancer cell potential particularities and 
related therapeutic targets [11]. In 2011 Hanahan and Weinberg [3] identified 
reprogramming energy metabolism as an emerging hallmark of cancer showing that 
scientists are rediscovering cancer metabolism as a way to target cancer. 
 Proliferating cancer cells exhibit considerably different metabolic requirements 
to most normal differentiated cells [7]. In order to support their high rates of 
proliferation, cancer cells consume additional nutrients and divert those nutrients into 
macromolecular synthesis pathways. Metabolic pathways must therefore be rewired 
in such a way that balances biosynthetic processes with sufficient ATP production to 
support cell growth and survival [8].  
Over the past decade, a more complex picture of cancer cell metabolism has 
emerged. Many cancers show increased glucose uptake and enhanced glycolytic rates, 
suggesting that metabolic alteration provides a growth advantage for tumour cells by 
also supporting the production of intermediates for the synthesis of lipids, proteins 
and nucleic acids [58, 59]. Although is not clear  whether these metabolic alterations 
are specific to cancer or just reflect the increased proliferation of tumour cells, 
different oncogenic signalling pathways target distinct components of the metabolic 
network. In order to support uncontrolled proliferation, evasion of growth-inhibitory 
signals, cell migration and the dissemination of metastatic cells into distant tissues, 
cancer cells need to modify their metabolism [59]. 
Otto Warburg, pioneer in the study of respiration, found that even under 
normal oxygen concentrations, cancer cells metabolize glucose preferentially by 
glycolysis, although it is a less efficient pathway for producing ATP than oxidative 
phosphorylation [11, 60, 61]. It has been demonstrated that the key components of 
the Warburg effect, increased glucose consumption, decreased oxidative 
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phosphorylation, and accompanying lactate production, are also distinguishing 
features of oncogene activation [62]. The increased glucose uptake, that often 
accompanied the metabolism of glucose by aerobic glycolysis, has proved useful for 
tumour detection and monitoring by [18]fluorodeoxyglucose positron emission 
tomography (FDG–PET) imaging [8, 60].  
The metabolic phenotype of tumour cells is controlled by intrinsic genetic 
mutations and internal responses to the tumour microenvironment. Oncogenic 
signalling pathways controlling growth and survival are often activated by the loss of 
tumour suppressors (such as p53), activation of oncoproteins (such as PI3K or mTOR) 
or transcription factors (for example HIF-1 or MYC) [60, 63].  
 
4.1. Aerobic glycolysis 
It was thought that proliferating tumour cells tend to rely on aerobic glycolysis 
to generate ATP and divert carbon from glucose into precursors for the synthesis of 
nucleotides, proteins, and lipids needed to duplicate cell biomass and genome at each 
cell division. This switch to aerobic glycolysis is induced by oncogenic lesions that 
induce the expression and activation of several glycolytic enzymes [18]. However, if 
glucose is completely converted to lactate the preferential metabolic pathway supplied 
by intermediates of glycolysis will be Phosphate Pentose Pathway (PPP), having as 
main goal the synthesis of nucleotides. Considering that glucose is preferentially 
catabolized to lactate, rather than fully metabolized to carbon dioxide (CO2) via 
mitochondrial oxidative phosphorylation (OXPHOS), not exploiting the full capacity of 
oxidative metabolism of glucose to produce avidly needed ATP [10, 18]. Malignant cells 
must have another carbon source to supply the tricarboxylic acid cycle (TCA cycle), 
whose intermediates will supply lipids and aminoacid metabolic pathways, as well as 
CO2 for OXPHOS. The rate of glycolysis in tumours is usually higher than in normal 
tissues, mainly to support DNA replication through PPP, rather than to maintain 
normal ATP levels as it is presented by some studies [9]. Maintenance of a high 
glycolytic flux requires nicotinamide adenine (NAD+) which may be efficiently 
generated from the conversion of pyruvate into lactate. This metabolic conversion 
makes glycolysis self-sufficient as long as elevated glucose uptake is possible [10]. 
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Since tumours have a high rate of glycolysis, lactate, the end product, is 
produced in large quantities in tumours and has been correlated with increased 
metastasis, tumour recurrence, and poor outcome. Some cancer cells generally export 
lactate, which acidifies the tumour environment, leading to a local inflammatory 
response that attracts immune cells such as macrophages, which secrete cytokines and 
growth factors that drive tumour cell growth and metastasis [64, 65]. In the tumour 
cell milieu, lactate impairs the adaptive immune response, disabling immune 
surveillance [18].  
Hypoxia has been considered the main stimulus for this metabolic switch into 
glycolysis [19, 20]. Besides lactate being considered a waste product, it was described 
as an important in an metabolic symbiosis in tumours. In this scenario, oxygenated 
oxidative tumour cells can use lactate instead of (or in addition to) glucose, thereby 
sparing the available glucose which can then diffuse deeper into the tumour to fuel 
hypoxic cells located farther away from tumour blood vessels. Central and less 
oxygenated glycolytic cells produce lactate as the end product of glycolysis that will be 
consumed by the peripheral oxygenated glycolytic cells [19, 66].  
Lactate metabolism is dependent on the action of lactate dehydrogenase 
enzymes (LDHs) as well as on the monocarboxylates membrane transporters (MCTs).  
 
4.2. Lactate dehydrogenases (LDHs) 
Lactate dehydrogenases (LDHs) comprise a group of five tetrameric isozymes 
from the combination of two subunits A and B. Depending on their composition these 
enzymes can catalyse the forward and backward conversion of pyruvate to lactate with 
concomitant interconversion of NADH and NAD+ [11, 12]. LDHA is the gene that 
codifies the predominant subunit and is specific of highly glycolytic tissues including 
skeletal muscle. It has a higher affinity for pyruvate favouring the conversion of 
pyruvate into lactate. The LDHB gene codifies a subunit that is ubiquitously expressed 
and is the predominant isoform in heart muscle, converts lactate into pyruvate which 
allows cells to use lactate as a nutrient source for oxidative metabolism (heart tissue 
and neurons), and/or for gluconeogenesis (in the liver and kidney) [18]. 
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Many tumours, mainly the highly glycolytic ones, have higher LDHA levels than 
normal tissues, which correlate with a poor prognosis [13, 14]. LDHA and pyruvate 
dehydrogenase kinase (PDK) are upregulated in solid tumours in response to hypoxia 
by the expression of hypoxia inducible factor 1 α (HIF1-α). PDK inactivates pyruvate 
dehydrogenase (PDH) and prevents the import of pyruvate into the mitochondrial 
matrix, whereas LDHA reduces the pyruvate into lactate and thereby regenerates the 
NAD+ stock necessary to maintain the glycolytic flux self-sufficient [11]. LDHA was 
identified as a direct target gene of the c-Myc oncogenic transcription factor which, 
when inhibited, induces oxidative stress and inhibits tumour progression [12].  
It has been reported that, unlike LDHA, LDHB is silenced by promoter 
methylation in several tumours [67, 68], suggesting that tumours preferentially 
express LDH isoenzymes with a high LDHA gene product content. LDHB was linked to 
tumour growth in basal-like breast cancers being present in tumours with higher 
metastatic potential [15, 16]. As expected on the basis of its enzymatic function, high 
LDHB was associated with oxidative, basal-like phenotype [16]. LDHB-high tumours 
coexpressed MCT1 suggesting that these tumours use pyruvate or lactate as an energy 
source providing an alternative means of energy generation and the ability to adapt to 
the tumour microenvironment [15]. 
 
4.3. Monocarboxylate transporters 
MCTs constitute a family of 14 transporters, encoded by the evolutionary 
conserved monocarboxylate transporter (SLC16) gene family, that transport single-
carboxylate molecules across biological membranes. MCTs are predicted to have 12 
transmembrane helices (TMs) with intracellular C- and N-termini and a large cytosolic 
loop between TMs 6 and 7. The TM regions are well conserved, the C and N-terminus 
regions and intermediary loop sequences being responsible for the variability between 
the 14 members. Only four members of the family (MCTs1–4) have actually been 
demonstrated to facilitate proton-linked monocarboxylate transport of pyruvate, 
lactate and ketone bodies [69]. These four transporters have a crucial role on the 
lactate homeostasis in both normal cells and cancer cells allowing the influx and the 
efflux of lactate [18]. 
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The major differences between the isoforms are their relative substrate and 
inhibitor affinities, the regulation of their expression, their tissue distribution and 
intracellular localization. MCT1 is expressed in almost all tissues, sometimes in 
conjunction with other MCT isoforms, and plays an active role in the uptake of lactate 
in the heart, skeletal muscle, red blood cells and liver [17]. MCT2 expression is 
confined to tissues that take up lactic acid in significant quantities for use as a 
respiratory fuel (neurons) or for gluconeogenesis (liver parenchymal cells and proximal 
kidney convoluted tubules) [69]. MCT3 is only expressed in retinal pigment epithelium 
and choroid plexus epithelia, mediating the efflux of metabolic lactate in the retina 
[66]. MCT4 is widely expressed and especially so in glycolytic tissues such as fast 
skeletal muscle fibbers, astrocytes, white blood cells, chondrocytes, and some 
mammalian cell lines [69]. 
Most solid tumours are known to rely on glycolysis, producing large amounts of 
lactate that has to be exported into the extracellular milieu, contributing to the acidic 
microenvironment and preventing the acidification of the intracellular milieu [18, 66]. 
MCTs play a dual role in the maintenance of the hyper-glycolytic phenotype of some 
cancers, allowing the maintenance of the high glycolytic rates by performing lactate 
efflux, and pH regulation by the co-transport of protons [66]. MCTs also allow the 
import of lactate into cells that have the ability to use it as a carbon and energy source. 
In the cancer context, MCT1 and MCT4 are the two major MCTs expressed in 
tumour cells where high levels of these transporters predict poor outcome. Elevated 
levels of MCT1 have been detected in breast, colorectal, gastric, and cervical cancer as 
well as in neuroblastoma and glioma [18]. MCT4 expression is highly elevated in renal 
cell carcinoma as well as in cervical and prostate cancer [20]. The expression of MCT4 
is upregulated by Hypoxia-inducible factor 1 α (HIF-1α), which is the main glycolytic 
transcription factor induced by oxidative stress and hypoxia [20]. 
 
4.4. Metabolic Symbiosis  
The gradient levels of O2 in tumours are dependent of the distance from a 
functional blood vessel. Tumour cells closer to blood vessel would be more oxygenated 
and the most distant cells would be less rich in oxygen. These last ones will have high 
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levels of HIF-1 expression that would increase the uptake of glucose and its conversion 
to pyruvate which is then converted to lactate by LDHA. This lactate produced by the 
hypoxic cells will be secreted from the cell via MCT4. As Sonveaux et al (2008) [19] 
described, aerobic tumour cells, closer to an oxygen source, express MCT1 in order to 
import lactate and use it as an energy source with the help of LDHB in the presence of 
O2. Lactate is a preferred substrate relative to glucose and glucose can then diffuse to 
fuel glycolysis of distant hypoxic tumour cells as described in figure 2 [19, 20].  
 
Figure 2 - Lactate-based metabolic symbiosis in tumours (based on Sonveaux et al, 2008 [19]) – high 
levels of HIF-1 in tumour cells in hypoxic increases the uptake of glucose via glucose transporters (GLUT) 
and its conversion to pyruvate that is converted to lactate by LDHA that would be exported by MCT4. 
Aerobic tumour cells, closer to O2 source, import lactate via MCT1 and convert it back to pyruvate via 
LDHB. Aerobic tumour cells preference for lactate as an energy souse facilitates the delivery of glucose 
to the hypoxic regions of the tumour. 
 
5. VEGF and AML 
VEGF is the main effector in angiogenesis, the process of new blood vessel 
formation, which is a crucial step in tumourigenesis. Besides its role in angiogenesis, 
VEGF has also been described as a survival factor for cancer cells, including AML [21]. 
Dysregulation of VEGF production was suggested to have a major impact on 
leukemic growth and constitutes an important step in the progression of AML [22]. Via 
paracrine pathways, AML cells increase the production of VEGF, which activates 
endothelial cells in the BM to secrete several growth factors or cytokines (such as 
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macrophage colony-stimulating factor, granulocyte colony-stimulating factor and 
interleukin-6) which stimulate AML cell growth [23, 24]. AML cells increase the 
production of VEGF via autocrine pathways, which binds to the VEGF receptor-2 on 
leukemic cells, increasing AML cell survival [21, 70]. 
Filipa Brito (2012) [25], reported that the presence of lactate and VEGF 
modulate the expression of MCT1, MCT4, LDHA and LDHB in HL60 cells, a human 
myeloblastic leukaemia cell line. These results suggest the existence of a functional 
loop of lactate influx/efflux mediated by MCT1 and MCT4 which is also maintained due 
to the catalytic action of LDHA and LDHB. The use of lactate as a carbon and the 
regulation of nucleotide synthesis by VEGF, was also demonstrated [25].   
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Aim 
 
Cancer cells exhibit a metabolic profile which maximizes their fitness within 
their microenvironment and gives them an advantage in term of proliferation and 
survival. Here we will seek to determine the role of lactate metabolism in AML, both 
dependent on, and independent of, VEGF stimuli.  
In this thesis, we will use in vitro models of two different AML lineages, 
monoblastic and erythroblastic, as well as BM samples from AML patients. 
The specific aims will be to evaluate: 
- the metabolic profile of AML cells exposed to lactate and/or VEGF; 
- the effect of lactate and VEGF in the expression of MCT1, MCT4, LDHA and 
LDHB; 
- the influence of lactate and VEGF on several cell features, namely cell cycle 
duration, proliferation rate and cell death, and 
- the expression profile of MCT1 and MCT4 in BM samples from AML patients. 
With this study we aim to increase our knowledge about how VEGF modulate 
the metabolism of different AML types. 
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Materials and Methods 
 
1. Cell culture 
Cell lines were obtained from American Type Culture Collection (ATCC): HL60 
(ATCC®:CCL-240TM); a human promyelocytic (monoblastic) cell line, and HEL 
(ATCC®:TIB-180TM), a human erythroblastic leukaemia cell line. 
Cells were maintained at 37°C in a humidified 5% CO2 environment in RPMI 
1640 medium  (31870, Gibco - Life Technologis Inc) supplemented with 10% fetal 
bovine serum (FBS) (S 0615, Biochrom), 1% Antibiotic-Antimycotic (AA) (15240062, 
Anti-Anti, Invitrogen - Life Technologies Inc) and  1% Glutamine (25030-081, Invitrogen 
- Life Technologies Inc). Cell number was determined with the help of a Bürker 
counting chamber.  
Lactate (1065222500, Merck) was used at a concentration of 10mM and 
vascular endothelial growth factor (VEGF) (V7259, Sigma-Aldrich®) was used at a 
concentration of 25ng/mL plus 5U/mL heparin (H3149, Sigma-Aldrich®). 
 
2. Western Blotting   
Cell extracts were performed using Radio-Immunoprecipitation Assay (RIPA) 
buffer (Appendix I), mixed by vortex and stored at -20°C. Cell extracts were centrifuged 
at 14000 rpm for 4 min at 4°C, and proteins were denatured by adding loading buffer 
(Appendix I) with 10% β-mercaptoethanol (M3148, Sigma-Aldrich®) to each sample 
and boiling at 95-100°C for 15 min. After that, samples were centrifuged at 14000 rpm 
for 2 min at 4°C and then chilled on ice.  
Proteins were separated in a 15% sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE) in a MINI-PROTEAN Tetra Electrophoresis System (Bio-Rad) 
at 130V for approximately 1h30, into  Tris-Glycine-SDS buffer (TGS 10x, 161-0772, Bio-
Rad). After electrophoresis, proteins were transferred onto a Immun-Blot® PVDF 
membrane, previously activated with methanol, with a Mini Trans-Blot® 
Electrophoretic Transfer Cell (Bio-Rad), at 60V and at 4°C, ON. Membranes were 
blocked, to avoid non-specific binding, using 5% (w/v) skimmed milk in phosphate 
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buffered saline (PBS) 0.1% (v/v) Tween 20 for 2h at room temperature (RT), with 
shaking. For protein detection, membranes were incubated with the primary 
antibodies anti-LDHA (SAB1100050, Sigma-Aldrich®), anti-LDHB (WH00003945M1, 
Sigma-Aldrich®), at 1:250, respectively in 5% (w/v) skimmed milk in PBS 0.1% (v/v) 
Tween 20, at 4°C, ON, with shaking.  
The membrane was rinsed 3 x 5 min, with PBS 0.1% (v/v) Tween 20, to remove 
unbound primary antibody. Membranes were then incubated for 2h at RT with a 
secondary antibody, the anti-rabbit IgG-conjugated horseradish peroxidase (HRP) 
(31460, Thermo Scientific) at 1:5000 in 5% (w/v) skimmed milk in PBS 0.1% (v/v) Tween 
20. After rinsing the membrane 3 x 5 min with PBS 0.1% (v/v) Tween 20, 
immunoreactive bands were detected by using SuperSignal® West Pico 
Chemiluminescent Substrate (34080, Thermo Scientific) in a ChemiDoc XRS System 
(Bio-Rad) with Image Lab software.  
β-actin was used has endogenous control to normalize the protein levels 
between samples. For that, membranes were rinsed 3 x 5 min, with PBS  0.1% (v/v) 
Tween 20 and incubated with anti β-actin (A5441, Sigma-Aldrich®) at 1:1000 in 5% 
(w/v) skimmed milk in PBS 0.1% (v/v) Tween 20 (Appendix I), at 4°C, ON, and then 
revealed as describe above. Bands were analyzed and quantified using Image J 
software (rsb.info.nih.gov/ij/). 
 
3. Immunofluorescence  
HL60 and HEL cells (1 x 106 cell/mL), control and exposed to lactate (10 mM) 
and/or VEGF (25 ng/mL) plus 5U/mL heparin for 24h were collected and centrifuged at 
1200 rpm for 2 min and resuspended in 500 µl of PBS. Cell suspensions (100 µl) were 
transferred onto a glass slide and centrifuged in a Cytospin at 1200rpm for 5 min. 
Cells were fixed with methanol, for 30 min. Each group of cells was delimitated 
with a circle made with a hydrophobic pen (S2002, Dako) and then PBS 0.1% (w/v) BSA 
was added for 30 min at RT, to block unspecific binding. Each circle (except the 
negative controls, for secondary antibody specificity) was incubated with 50 μL of 
primary antibodies anti-FLT1 (sc-9129, Santa Cruz Biotechnology Inc), anti-KDR (sc-505, 
Santa Cruz Biotechnology Inc), anti-MCT1 (AB3538P, Millipore) and anti-MCT4 (SC-
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50329, Santa Cruz) diluted 1:100 in PBS 0.1% (w/v) BSA, overnight at 4°C, in a humid 
chamber. In the negative controls 50μL PBS 0.1% (w/v) BSA was added. 
Slides were rinsed 3 times for 5 min, with PBS  and then all circles with cells 
were incubated with secondary antibody anti-rabbit conjugated with Alexa Fluor© 488 
(A-11034, Invitrogen - Life Technologies Inc) diluted 1:1000 in  PBS  0.1% (w/v) BSA for 
2 hours at RT, protected from light. 
After incubation, slides were rinsed 3 times for 5 min with  PBS  and then 
mounted with Vectashield mounting medium with DAPI (4’-6-diamidino-2-
phenylindole) (H-1200, Vector Labs) and the coverlids were sealed with nail polish. 
Slides were observed under an Axio Imager.Z1 microscope (Zeiss). Images were 
acquired with Cytovision® software and processed with ImageJ software 
(imagej.nih.gov/ij/). 
 
4.  Cell cycle  
Cell cycle was analysed by Fluorescence-activated cell sorting (FACS). Cells 
(HL60 and HEL; 1 x 105 cell/mL) were plated, synchronized as described above. 
Afterwards, medium was supplemented with 1% FBS and 10mM lactate and/or 25 
ng/mL VEGF plus 5U/mL heparin and maintained at 37°C and 5% CO2. Cell samples 
(500µL) were collected by centrifugation (1200rpm, 3 min) at 2, 4, 8, 26, 32h of 
incubation, fixed in 70% ethanol and maintained at 4°C for, at least 24 hours.  
The determination of the amount of DNA per cell was performed with 
propidium iodide (PI), in order to determine the percentage of cells in each phase of 
the cell cycle. PI is a fluorescent DNA intercalating compound, allowing the relative 
quantification of cellular DNA content. For PI labelling, cells were centrifuged at 1500 
rpm for 5 min and cell pellet was resuspended in 100 μL of 50 μg/mL PI solution 
(Appendix I) and incubated at 37°C for 40 min. After incubation, 300 μL of PBS was 
added and cells were centrifuged at 1500 rpm, 10 min at 4°C. The supernatant was 
discarded and cells were resuspended in 200 μL PBS 0.1% (w/v) BSA and analysed by 
FACS (FACScalibur - Becton Dickinson). The percentage of cells in each cell cycle phase 
was assessed using FlowJo Software, excluding dead cells and cell aggregates. Average 
and standard deviation were calculated and statistical analysis was performed. 
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5.  Cell Cycle duration  
Based on Eidukevicius et al [71], 2005 from PI labelling was used to determine 
the duration of each cell cycle phase and the total cell cycle duration.  
The proposed method is based on two assumptions. The first assumption, i.e., 
the labelled cell mortality or exit from the cell cycle during the period of measurement 
is negligible, can be regarded as reasonably simple and generally acceptable and the 
second assumption is that the number of labelled cells traversing the cell cycle per unit 
time is constant [71]. 
With the data obtained from FACS analysis described above, it is possible to 
obtain the number of divided G1 cells (G1ld), divided S cells (Sld), undivided S cells 
(Slu) and undivided G2 cells (G2lu) what would give rise to the time of S phase (Ts), G2 
phase (TG2) and G1 phase (TG1). Ts, TG2 and TG1 together correspond to the total 
duration of cell cycle. 
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6.  Nuclear magnetic resonance (NMR) 
Cells (5 x 107 cell/mL) were submitted to starvation as described above. In order 
to understand the metabolism of lactate, cells were exposed to 10nM 13C-[U]-lactate 
(660817, Sigma-Aldrich®), and/or 25 ng/mL VEGF plus 5U/mL heparin in 40mL of RPMI 
medium supplemented with 1% FBS and 1% AA and maintained at 37°C and 5% CO2. 
After 24 hours cells were centrifuged at 1200 rpm for 2 min, the supernatants were 
collected and stored at -20°C and the pellets were washed in PBS.  
To separate the organic and aqueous phases, methanol and chloroform 
extraction was performed in cell pellets. To calculate the volume of methanol added 
for each sample, cell pellets were weighed (4ml methanol/1g weight pellet). Then 
sequentially, 2 volumes of water were added, mixed and incubated on ice for 5 min; 1 
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volume of chloroform was added and mixed, and 1 volume of water was added and 
incubated on ice for 10 min. Finally, samples were centrifuged at 4000 rpm for 15 min 
at 4°C, in order to define organic (lower) and aqueous (upper) phases that were 
collected separately and stored at -20°C until they were lyophilized, in Speed Vac Plus 
Savant SC110A.  
Samples were dissolved in deuterated water (D2O) and 4% (v/v) azide (N3) / 
4,4-dimethyl-4-silapentane-1-sulfonic acid (DSS) solution (1:10). 50μl of D2O and 4% 
(v/v) N3 / DSS solution was also added to supernatants. NOESY 1DPR 1D (1H), HSQC 2D 
(1H, 13C) and TOCSY 2D (1H, 1H) spectrums were obtained in a magnetic field of 800 
MHz at 25°C in UltrashiedTM 800 Plus (Bruker) with TXI probe and COSY 2D (13C, 13C) 
spectrum was obtained in a magnetic field of 500 MHz at 25°C in UltrashiedTM 500 
Plus (Bruker) with 13C Dual probe. Software used in acquisition was Topspin 2.1 on 
avance 800 (Bruker) and 21 spectrums analysis were done according the chemical 
shifts supported with the Human Metabolome database (HMDB) 
(http://www.hmdb.ca/) and Chemomx NMR suite 7.6. 
Following the results obtained for the lactate metabolism, cells were also 
exposed to 4mM of 13C-[U]-D-glucose (CC860P20,  Cortecnet) and 16mM of D-glucose 
(G8270, Sigma-Aldrich®) and 25 ng/mL VEGF plus 5U/mL heparin with or without 
10mM lactate in 40mL of RPMI medium supplmented with 1% FBS and 1% AA, 
maintained at 37°C and 5% CO2. Cells were then treated as described above. 
 
7. Apoptosis analysis by Flow Cytometry  
HL60 and HEL cells (1 x 104 cell/mL) were synchronized as described above. 
Cells were then plated in 48 plate tissue dishes at a 1 x 104 cells/mL concentration and 
exposed to 13C-[U]-lactate and/or VEGF plus 5U/mL heparin in 40mL of RPMI medium 
supplemented with 1% FBS and 1% AA. 
Cells exposed to the different experimental conditions were collected at 2, 4, 8, 
26 and 32h and centrifuged at 1200 rpm for 3 min and washed with PBS 0.2% (w/v) 
BSA. The distinction between apoptosis and necrosis was performed using labelled 
Annexin V and PI. In live cells PS is in the cytoplasmic surface of the cell membrane 
and, with the apoptosis process, is translocated to the outer surface of the cell 
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membrane. Annexin V binds to phosphatidyl serine (PS) that is present in the external 
surface of apoptotic cells membrane. PI stains necrotic cells and not live and apoptotic 
cells. Necrotic cells have pores in their membrane that allows PI to enter and bind to 
the nucleic acids in the cell. Staining was performed using 1 μl FITC Annexin V (640906, 
Bio Legend) and 1 μl PI solution (50μg/mL) in 100 μl of annexin V binding buffer per 
sample and incubated at RT and in dark for 15 min. After incubation, samples were 
resuspended in 200 μl of annexin V binding buffer (Appendix I) and analyzed by flow 
FACS. 
 
8. Chromatin Immunoprecipitation (ChIP)  
HL60 and HEL cells we synchronized, control and exposed to 10mM lactate 
and/or 25 ng/mL VEGF plus 5U/mL heparin). 
HL60 and HEL cells (5 x 107 cell/mL) were synchronized as described above. 
Cells were then exposed to lactate (10mM) and/or VEGF (25 ng/mL) plus 5U/mL 
heparin in 40mL of RPMI medium supplemented with 1% FBS and 1% AA.  
After stimulation (24h), 37% formaldehyde (Merck) was added to cells to a final 
concentration of 1% (v/v) and incubated for 10 min at RT (to cross-link DNA and 
proteins) and then formaldehyde was quenched by addition of 125mM glycine and 
incubated for 5 min at RT. Then cells were harvested and centrifuged at 1200 rpm for 2 
min and 500 μL of ChIP lysis buffer (kch-onedIP-060, Diagenode) were added to cell 
pellets and stored at -70°C.  
Cell pellets were thawed on ice and sonication was performed (19 intermittent 
cycles of 30 seconds each one). Chromatin fragmentation was evaluated by gel 
electrophoresis, 5 μL of chromatin were separated by a 1.2% (w/v) agarose gel 
electrophoresis in TBE buffer (10X TBE, EC-860, National diagnostics) stained with 
0.05% (v/v) ethidium bromide. Fragmented chromatin was stored at -70°C. ChIP was 
performed using OneDay ChIP kit (kch-onedIP-060, Diagenode) accordingly to 
manufacturer’s protocol. FOXM1 antibody (sc 26688, Santa Cruz Biotech) (target) and 
a rabbit non-immune IgG (kch-onedIP-060, Diagenode) were used. Amplification and 
analysis of Immunoprecipitated (IP’d) DNA was done through qRT-PCR, accordingly to 
manufacturer’s protocol, in an ABI PRISM 7900HT Sequence Detection System (Applied 
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Biosystems) (Table 1) using specific primer flanking c-Myc binding site in MCT1 
promoter (pMCT1; Table 2). Data were analyzed in SDS 2.4.1 software (Applied 
Biosystems) and relative occupancy of the immunoprecipitated factor at specific loci 
was calculated using the following equation: 
2(CtNegCtl -  CtTarget) 
CtNegCtl and CtTarget are the average threshold cycles of PCR done in 
triplicates on DNA samples from negative control ChIP  and targeted ChIP.  
 
Table 1 - IP’d DNA quantitative Real-Time PCR program 
Stage Cycles Temperature (°C) Time 
Activation 1 50 2 min 
Initial Denaturation 1 95 10 min 
Denaturation 
40 
95 15 sec 
Anneling; Elongation 60 1 min 
Melting  
95 
60 
60 
15 secs 
15 secs 
15 secs 
 
Table 2 - Primers used in IP’d DNA quantitative Real-Time PCR 
Reference Primer (5’-3’) 
pMCT1 
For: GTATTACTCACTAGTAGTACTTGGC 
Rev: GAGATTGAAGAAGAGTAGAGATTGG 
 
 
9. Immunohistochemistry 
BM paraffin blocks from LMA patients belong to the archive of the Pathology 
Department of the Instituto Português de Oncologia de Lisboa de Francisco Gentil, 
were retrieved as well as and clinical data of the patients.  
Paraffin sections (2µm) were treated in xylol for 10 min to remove paraffin and 
tissue hydratation was performed in a stepwise sequence of decreasing concentrations 
of ethanol for 5 min and finally in running water for 10 min.  
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The sections were then incubated with anti-MCT1 (1:400; AB3538P, Millipore) 
and MCT4 (1: 150; SC-50329, Santa Cruz Biotech) at RT for 1 hour and then incubated 
with EnVision/HRP rabbit/mouse (Dako, K5007) detection staining system for 30 s at 
RT. After washing in TBS, the visualization signal was developed with 3,3’-
diaminobenzidine (DAB) solution, and all the slides were counterstained with Mayer’s 
hematoxylin.  
 
10.  Quantitative Real-Time PCR of BM samples from AML patients 
Ribonucleic acid (RNA) from BM samples from LMA patients was obtained from 
Hemato-oncology laboratory from IPO Lisboa.  
cDNA was synthesized from 1μg RNA with SuperScript II Reverse Transcriptase 
(18080-44, Invitrogen - Life Technologies Inc), according to the manufacturer’s 
protocol. As initiators random hexamers (11034731001, Roche) were used. cDNA 
synthesis was performed in a T3000 thermocycler (Biometra), using the following 
conditions (Table 3). 
Table 3 - Program used for RT-PCR. 
Stage Cycles Temperature (°C) Time 
Denaturation  1 70 10 min 
Cooling  1 4 5 min 
cDNA synthesis  1 42 4h 
Inactivation  1 75 15 min 
Cooling   4 Pause 
 
Quantitative Real-Time PCR (qRT-PCR) was performed for each sample. Each 
reaction mixture was performed on 25 μL, containing 1 μl cDNA, 12.5 μL Power SYBR 
Green PCR Master Mix (4367659, AB), 0.15 μl of forward and reverse primers (10μM) 
(Table 4), and sterile bidestilled water up to 8.3 μl. The housekeeping gene used to 
normalize the samples was 18S rRNA.  
Each PCR experiment included one non-template control well. Real-time PCR 
was carried out in an ABI Prism® 7900HT Sequence Detection System (Applied 
Biosystems), according to the program described in the Table 5. 
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Table 4 - Primers used in qRT-PCR. 
Reference Primer (5’-3’) 
MCT1 
For: GCTGGGCAGTGGTAATTGGA 
Rev: CAGTAATTGATTTGGGAAATGCAT 
MCT4 
For: CACAAGTTCTCCAGTGCCATTG 
Rev: CGCATCCAGGAGTTTGCCTC 
18S rRNA 
For: GCCCTATCAACTTTCGATGGT 
Rev: CCGGAATCGAACCCTGATT 
 
Table 5 - Program used for real-time qRT-PCR. 
Stage Cycles Temperature (°C) Time 
Initial denaturation 1 95 2 min 
Denaturation 
45 
95 15 secs 
Annealing 60 1 min 
Melting  
95 
to 
60 
 
15 min 
 
Cooling  40 10 secs 
 
11.  Statistical analysis  
The statistical significance of results was evaluated by 2-way ANOVA using 
GraphPad Prism 5 software. Data’s were considered significant when p<0.05. 
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Results 
 
1. NMR - Metabolic profile of HL60, but not HEL, is modulated by lactate and VEGF 
It has been shown that cancer cells metabolic fitness is an advantage for cells to 
survive in tumour/organ microenvironment. By NMR, we assessed the metabolic 
profiles of HL60 and HEL cells exposed to lactate, VEGF and both. 
As published by Brito (2011), in HL60 cell line NMR analysis showed that 
carbons from lactate are incorporated in acetate, amino acids (alanine and glutamate) 
and malate, an intermediate of the TCA cycle (Figure 3). The incorporation of lactate 
happens in the presence and absence of VEGF. However, in HL60 cells exposed to 
VEGF, nucleotides were detected (Figure 3). Glucose (not 13C-labeled) was detected in 
control cells and in cells cultured with 13C-lactate. Nevertheless, in cells cultured in the 
presence of VEGF, glucose is not detected. 
 
Figure 3 - HL60 metabolic profile by NMR spectroscopy. 
13
C-
1
H HSQC spectra of the aqueous extracts of 
HL60 cells cultured in DMEM medium (blue); DMEM + 
13
C-lactate (red); DMEM + VEGF (green); and 
DMEM + VEGF + 
13
C-lactate (black). When the cells were grown in the presence of VGEF, the glucose 
(Gluc) is absent and there is the appearance of resonances due to nucleotides (NT). In the case of 
growth in presence of VEGF and 
13
C-lactate appear resonances due to malate (Mal). There are some 
resonances that appear with lactate that should be further analysed. 
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In order to verify if, in HL60 cell line stimulated by VEGF, glucose is the organic 
source used to produce ribose/desoxiribose included in nucleotides, we performed an 
NMR analysis of cells exposed to 13C-glucose. 
By NMR spectroscopy, it was possible to see that glucose is not the compound 
used to produce nucleotides in HL60 cells (Figure 4). 
 
 
Figure 4 - HL60 metabolic profile by NMR spectroscopy. 
13
C-
1
H HSQC spectra of the aqueous extracts of 
HL60 cells cultured in RPMI with 20% of the glucose U-
13
C labeled (blue); plus VEGF (green);  VEGF + 
lactate (black). The cells do not show any metabolic difference growing in the presence or absence of 
VEGF. The main metabolites present are nucleotides, lactate and glucose, being lactate the only 
compound clearly 
13
C labelled. 
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Concerning HEL aqueous extracts, NMR analysis showed no metabolic 
difference between cells cultured in the presence or absence of VEGF. Whenever 
lactate was present, it was converted into malate and proline (Figure 5). Glucose is not 
detected in any culture condition. 
 
 
Figure 5 - Hel metabolic profile by NMR spectroscopy. 
13
C-
1
H HSQC spectra of the aqueous extracts of 
HEL cells cultured in RPMI medium (blue); RPMI + 
13
C-lactate (red); RPMI + VEGF (green); and RPMI + 
VEGF + 
13
C-lactate (black). The cells do not show any metabolic difference growing in the presence or 
absence of VEGF. When the cells grow in the presence of 
13
C-lactate (with and without VEGF) the 
resonances due to malate (Mal) and proline appear. 
 
 
Regarding, the percentage of lactate and 13C-lactate in HL60 and HEL, it was 
observed that the amount of 13C-lactate is higher in HL60 (67 %) than in HEL (24 %). In 
the presence of VEGF the intake of 13C-lactate decreases in HL60 (24%) and remains 
the same in HEL (Figure 6). 
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Figure 6 - Comparison between the lactate present in the HL60 and HEL cells. 
1
H-NMR spectra of the 
aqueous extracts of HL60 and HEL cells cultured in 
13
C-lactate with and without VEFG. When HL60 cells 
are cultured with 
13
C-lactate, 67 % of the intracellular lactate is 
13
C-labelled, while in the HEL cells it is 
only 24 %. When VEGF is present in the growth media the intracellular 
13
C-lactate is around 24 % for 
both cells lines. 
 
We therefore conclude that lactate and VEGF modulate the metabolic profile in HL60, 
but not in HEL cell line. 
 
2. Immunofluorescence - Expression of MCTs, but not LDHs, is modulated by lactate 
and VEGF, in both HL60 and HEL.  
HL60 and HEL cells showed different metabolic profiles to different 
stimulations, we sought to investigate if stimulation with lactate and/or VEGF affects 
the expression of proteins involved in lactate metabolism and transport. We assessed 
the expression of MCTs (MCT1 and MCT4) and LDHs (LDHA and LDHB) respectively in 
HL60 and HEL cells exposed to lactate, VEGF and both by immunofluorescence and 
western blotting. 
The influence of lactate and VEGF in the regulation of MCT1, MCT4, LDHA and 
LDHB protein levels in HL60 and HEL cell lines was assessed by immunofluorescence 
and Western-blotting. 
Brito (2011) observed that HL60 cells stimulated with lactate and/or VEGF 
exhibit higher levels of MCT1 (Figure 7A). In contrast, HEL cells decrease the expression 
of MCT1 after stimulation with lactate and/or VEGF (Figure 7B).   
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In both cell lines, the levels of MCT4 expression remain equivalent in all 
conditions except for the exposure with both lactate and VEGF (Figure 7).  
  
 
 
 
 
 
 
Figure 7 - Detection of MCT1 and MCT4 by immunofluorescence. HL60 cells were cultured in control 
conditions, in the presence of lactate, of VEGF and of both lactate and VEGF (N+V). A) HL60 cells, 
adapted from Brito (2011), magnification 100X and B) HEL cells. First and third rows correspond 
respectively to MCT1 and MCT4 (FIT-C; Green) immunoreactivity; second and fourth rows are merged 
images to DAPI (blue). Magnification 200x. 
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According to Brito (2011), HL60 cells express both LDHA and LDHB. However, 
no difference was observed in their expression with lactate and/or VEGF exposure 
(Figure 8).  The same was observed in HEL cell line (Figure 8). 
 
 
Figure 8 - LDHA and LDHB expression in HL60 and HEL cells, assessed by western-blotting. Cells were 
cultured in control conditions, in the presence of lactate, of VEGF and of both lactate and VEGF (N+V). 
HL60 cells-adapted from Brito (2011) and HEL cells. β-actin was used as endogenous control. 
 
3. Immunofluorescence - VEGF receptors 1 (FLT1) is the predominant VEGF receptor 
expressed in HL60 and HEL, and its expression and localisation are modulated by 
lactate and VEGF.  
NMR analysis showed that HL60 and HEL cells’s metabolism is influenced by the 
different stimulations, so it is important to investigate if lactate and/or VEGF are 
influencing the expression of the VEGF receptors. We assessed the expression of FLT1 
and KDR in HL60 and HEL cells exposed to lactate, VEGF and both, by 
immunofluorescence and western blotting 
HL60 cells stimulated with lactate and VEGF express higher levels of FLT1 than 
control cells. In HEL cells, lactate and VEGF by themselves or in combination increase 
the expression of FLT1. In HL60 and HEL cells, the exposure to both lactate and VEGF 
induces an apparent delocalisation of FLT1 to the nucleus (Figure 9). Nuclear FLT1 was 
also detected in HEL control and VEGF condition. 
A slight increase in KDR expression was observed in HL60 cells treated with 
VEGF and a decrease was observed in cells exposed to lactate in the presence or 
absence of VEGF.HEL cells barely express KDR (Figure 9).  
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Figure 9 - Detection of FLT1 and KDR in HL60 and HEL cells by immunofluorescence. HEL cells were 
cultured in control conditions, in the presence of lactate, of VEGF and of both lactate and VEGF (N+V). A) 
HL60 cells and B) HEL cells. First and third rows correspond respectively to FLT1 and KDR (FIT-C; Green) 
immunoreactivity; second and fourth rows are merged images to DAPI (blue). Magnification 200x. 
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4. Cell cycle and proliferation rate in HL60 and HEL cells exposed to lactate and 
VEGF  
  Increased proliferation and cell death resistance are hallmarks in cancer, so we 
investigated if lactate and VEGF were responsible for alterations in these cell features. 
Cell cycle analysis was performed to investigate the role of lactate and/or VEGF in cell 
cycle regulation in HL60 and HEL cell lines. 
Cell death (apoptosis and necrosis) was analysed to evaluate viability of cells 
cultured in lactate and/or VEGF. 
 
4.1 Cell cycle analysis by FACS – VEGF induces a shorter duration of cell cycle in HL60 
cell line, but not in HEL. 
In both cell lines, the percentage of cells in each phase of the cell cycle were 
equivalent in all conditions, within the same time point of cell culture (Figure 10). 
HL60 cells, 32h after VEGF stimulation, presented a longer G0/G1 and a shorter 
G2/M, comparing to control. In HL60 cells, exposed to both lactate and VEGF, a shorter 
G2/M phase is also observed (Figure 11).  Considering the cumulative cell cycle 
duration, a statistically significant reduction in cell cycle duration is observed in cells 
exposed to VEGF (Figure 11). 
HEL cells stimulated with lactate showed a longer G2/M when compared to 
control, 32h after stimulation. In cumulative cell cycle duration, no difference was 
observed between conditions (Figure 11). 
 
4.2   Cell death analysis by FACS - high proliferative rate of HL60 stimulated with 
VEGF culminates in higher apoptosis levels  
HL60 and HEL cell cultured in lactate and/or VEGF do not present statically 
significant differences in apoptosis. HL60 cells cultured in the presence of VEGF 
showed an increase in necrosis at 32h, independent of the presence of lactate (Figure 
12).  
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HEL cells cultured in the presence of lactate and VEGF at 32h showed 
statistically significant increase in necrosis, comparing to control (Figure 12).     
 
 
Figure 10 - Cell cycle analysis by FACS in HL60 and HEL. Cells were grown in control conditions and 
with lactate and/or VEGF and harvest at 0, 2, 4, 8, 26, 32 and 50h. Ethanol fixed cells were labelled with 
PI. A) HL60 and B) HEL cell line. Data are means of triplicates and error bars are standard deviation. 
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Figure 11 - FACS analysis showing the accumulated time spent in the different cell cycle phases by 
HL60 and HEL. Cells were grown in control conditions and with lactate and/or VEGF and harvest at 
several time points. Data are means of triplicates. Error bars represent standard deviation. *p<0.05; 
**p<0.01; ***p<0.001. 
 
 
HL60  HEL 
33 
 
2h 4h 8h 26h 32h
0
10
20
30
40
50
60
70
A
n
n
e
xi
n
 V
 p
o
si
ti
ve
 c
e
ll
s 
(%
)
  
2h 4h 8h 26h 32h
0
10
20
30
40
50
60
70
A
n
n
e
xi
n
 V
 p
o
si
ti
ve
 c
e
ll
s 
(%
)
 
2h 4h 8h 26h 32h
0
5
10
15
20
***
***
P
I  
p
o
si
ti
ve
 c
e
ll
s 
(%
)
  
2h 4h 8h 26h 32h
0
5
10
15
20
*
P
I  
p
o
si
ti
ve
 c
e
ll
s 
(%
)
 
 
Figure 12 - Cell death (apoptosis- annexin V and necrosis- PI) analyses by FACS, in HL60 and HEL cells. 
Cells were grown in control conditions and with lactate and/or VEGF and harvest at several time points. 
Data are means of triplicates. Error bars represent standard deviation. *p<0.05; **p<0.01; ***p<0.001. 
 
5. ChIP analysis - FOXM1 binding to MCT1 promoter region, is not induced neither 
by lactate nor VEGF, in HL60 and HEL cells. 
In previous studies from our group (submitted for publication), FOXM1 was 
found to be a transcriptional regulator of MCT1. Hence, in the present study a ChIP 
analysis was performed to investigate if Forkhead box protein M1 (FOXM1) is involved 
in the regulation of MCT1 expression in response to lactate and/or VEGF stimuli, in 
HL60 and HEL cell lines.  
 The relative occupancy of FOXM1 binding site in MCT1 promoter in HL60 cells 
decreased in cells cultured with lactate and/or VEGF, comparing to control. In HEL cells 
no differences were observed (Figure 13). 
HEL HL60 
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Figure 13 - Relative occupancy of FOXM1 binding site in MCT1 promoter region in HL60 and HEL cells. 
Cells were grown in control conditions and with lactate and/or VEGF for 24h. 
 
6. MCT1 and MCT4 expression in bone marrow (BM) samples from AML patients 
The in vitro studies showed that lactate and VEGF modulate the metabolic 
profile and the expression of MCTs, indicating that lactate metabolism might be 
relevant in AML. In order to validate our results we evaluated the expression profile of 
MCT1 and MCT4 in BM from AML patients, by RQ-PCR and immunohistochemistry.  
 
6.1 RQ-PCR- BM samples from AML patients express higher levels of MCT1 than 
MCT4 at diagnosis and disease relapse is accompanied by an increase in MCT1 
expression 
By RQ-PCR, it was observed that MCT1 and MCT4 have opposite levels of 
expression, in other words samples expressing high levels of MCT1 express low levels 
of MCT4 or the other way around. The majority of the cases express high levels of 
MCT1 at diagnosis (Figure 14A). At clinical relapse patients express higher levels of 
MCT1 than in remission (Figure 143B – B2 and BL2 case). 
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Figure 14 - Relative quantification of MCT1 and MCT4 expression in BM samples of AML patients, by 
real time PCR. MCT1 and MCT4 quantification at A) diagnosis and B) at diagnosis and at clinical 
remission of disease. Letters are different patients and numbers the same patient in clinical remission at 
different times. Quantification was relative to a pool of RNA from BM of control individuals and 18S RNA 
was used as endogenous control. Data are mean ± standard deviation of triplicates.  
36 
 
6.2 Immunohistochemistry - MCT1 and MCT4 are expressed in different settings of 
cells in BM samples from AML patients 
 By immunohistochemistry, it was observed that MCT1 and MCT4 do not 
colocalise as observed by immunohistochemistry (Figure 15). MCT1 is expressed in 
aberrant and large cells (leukemic blasts) whereas MCT4 is expressed in mature cells 
and in normal progenitor cells. 
 
 
The localisation of MCT1 or MCT4 positive cells in BM was also different. The 
results are depicted in Figure 15. MCT1 positive cells localise preferentially in 
paratrabecular regions (near bones) and MCT4 positive cells are diffusely localised 
(Figure 16).  
A 
B 
Figure 15 - MCT1 and MCT4 immunohistochemistry in BM samples from an AML patient. A) MCT1 and 
B) MCT4 are stained in brown (DAB – black arrowhead). Nuclei are staining in blue (hematoxylin). Bar 
scale: 100µm. 
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Figure 16 - Localization of MCT1 and MCT4 positive cells in BM samples from an AML patient. MCT1 
and MCT4 immunoreactivity was determined by immunohistochemistry in 27 AML cases. 
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Discussion 
 
Cancer metabolism is considered an emerging hallmark in cancer and as lactic 
acidosis is a frequent condition in AML patients, we sought to investigate the role of 
VEGF in lactate metabolism in in vitro models of two variants of AML, monocytic and 
erytroblastic leukaemia. 
As we observed in a previous work [25], HL60 monocytic cell line is able to 
metabolise lactate in order to produce amino acids and malate, both in the presence 
and absence of VEGF. The expression of MCTs that mediate the influx and efflux of 
lactate across cell membrane [69] was increased by lactate and VEGF exposure.  LDHs, 
responsible for the conversion of pyruvate in lactate (LDHA) and the opposite (LDHB), 
when detected their expression still unchanged between conditions [18]. In lactate 
producer cells the partnership between MCT4 and LDHA is expected, while in lactate 
consumer cells MCT1 and LDHB must be expressed. In HL60 cell line, by analysing the 
expression of these genes, it seems that a mixture of lactate producer and lactate 
consumer cells are present or cells are at the same time producing and consuming 
lactate. 
Interestingly, in the present work we verified that in cells stimulated by VEGF, 
glucose disappears and nucleotides are detected. Nucleotides are essential for cells to 
replicate DNA upon mitosis and glycolysis is a source of intermediates for pentose 
phosphate pathway (PPP) responsible for the synthesis of ribose and deoxyribose [72]. 
High rate of glycolysis is a feature described in several cancer types [7, 57, 60, 73–75] 
and lactate synthesis is the more efficient way for NAD+ regeneration in order to 
maintain glycolysis [10, 19, 76]. But, we verified by NMR that neither lactate nor 
glucose are used as organic sources to produce nucleotides, since nucleotides are not 
13C labelled. Other organic source is being used by HL60 cells to synthesize nucleotides 
and we must perform more experiments in order to identify it. 
We observed that in the absence of VEGF the percentage of 13C-lactate in cells 
is 67%, being decrease to 24% upon VEGF exposure, meaning that the percentage of 
lactate from glucose, which is not 13C labelled, increases. Taking together, the mixed 
MCT4/LDHA and MCT1/LDHB phenotypes can be justified by the fact that cells are able 
to consume lactate, as we saw by NMR analysis, but due to the high glycolytic rate, 
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resulting lactate must be secreted in order to avoid the decrease of intracellular pH.  
All these events may provide the appearance of a metabolic symbiosis between cancer 
cells, where some cells produce lactate to be used by other cells [19, 20].  
In HEL eythroblastic cell line, it was observed that lactate was converted into 
malate and proline and the presence of VEGF did not affect the metabolic profile. 
Glucose was not detected in any culture condition, indicating that it is fully consumed.  
Considering the expression of metabolic intervenients, MCT1, MCT4, LDHA and LDHB, 
no difference was observed in their expression between culture conditions, except for 
MCT4 in which a decrease is observed in cells exposed to both lactate and VEGF. In cell 
extracts, the percentage of 13C-lactate and lactate remains the same in the presence 
and absence of VEGF, indicating that VEGF does not regulate lactate metabolism and 
13C-lactate influx is reduced in this cell line, comparing with HL60. 
The synthesis of nucleotides, in HL60 cells upon VEGF stimuli, is in agreement 
with previous publications pointing out that VEGF might regulate the proliferation of 
HL60 cells [21]. We observed that HL60 cells exposed to lactate and VEGF express 
higher levels of FLT1 (VEGF receptor 1) than control cells. An apparent delocalisation of 
FLT1 into the nucleus was observed in cells exposed both to lactate and VEGF. For KDR 
(VEGF receptor 2), its expression remained unchanged in all conditions, except in VEGF 
condition in which a slight increase was observed. The influence of VEGF on HL60 cells 
proliferation was confirmed by cell cycle analysis, showing that cells exposed to VEGF 
have shorter cumulative cell cycle duration, at the cost of a shorter G2/M phase. 
Differences arise when data provide by FACS is analysed with the methods described in 
Eidukevicius et al (2005) [71] that provide a way to know the cumulative cell cycle 
duration. The time that is given by the different formulas corresponds to an 
accumulated time since is takes into account all cells analysed and not only one cell. 
Results represent the total cumulative cell cycle duration of all cells in the culture. The 
high proliferative rate, in cells exposed to VEGF, culminates in a higher percentage of 
cell death, comparing to control cells, which might be due to the exhaustion of the 
nutrients in the culture media. 
Regarding HEL cells, no consistent effect in cell proliferation was observed upon 
VEGF exposure. However, the expression of FLT1 was increased after lactate and VEGF 
stimuli, both in separation and combined. KDR was barely detected in these cells. 
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Despite the increase in cumulative time of G2/M phase duration in cells exposed to 
lactate at 32h of culture, no effect on the total cumulative cell cycle duration was 
observed.  
Concerning transcriptional regulation of MCT1 under lactate and VEGF stimuli, 
we assessed the role of FOXM1 as in previous works from our group where we saw 
that this transcriptional factor acts on MCT1 expression. In this AML model, we did not 
see a positive regulation of MCT1 by FOXM1 in lactate and/or VEGF exposed cells. 
Nevertheless, we saw that in HL60 the relative occupancy of MCT1 promoter by 
FOXM1 decreases in cells exposed to lactate and/or VEGF. For HEL, no difference was 
observed. 
In BM samples, the evaluation of MCT1 and MCT4 mRNA expression showed 
that in the majority of cases higher levels of MCT1 than MCT4 are expressed at 
diagnosis. The levels of expression of MCT1 are consistent with the percentage of 
blasts present in BM samples, corroborating the fact that MCT1 is expressed in 
leukaemia cells. In follow up samples, we preliminarily observed that MCT1 levels are 
increased upon clinical relapse. However, the studied cohort has few cases of follow 
up, being necessary to increase the number in order to enable strengthened 
conclusions.  
 By immunohistochemistry, MCT1 and MCT4 were detected in different set of 
cells. MCT1 was expressed mainly in large and aberrant cells consistent with the 
morphology of leukaemia precursor cell, while MCT4 was expressed in differentiated 
blood cells and in normal precursor cells. This can support the evidence of a 
functioning metabolic symbiosis between blasts and normal cells in which cancer cells 
take advantage of the lactate that normal cells produce and export. The presence of 
these MCT1 positive cells in the paratrabecular region, near the bones, is concordant 
with previous descriptions of blastic niches in BM from leukaemia patients [26, 77, 78]. 
VEGF is associated with a poor outcome in AML patients, and an VEGF signalling works 
on blasts in order to increase their proliferation and to provide a survival advantage 
[21, 79, 80]. VEGF has been described as an important homing factor in leukaemia 
metastasis [81–84], and VEGF signalling has been shown to be important in the 
establishment of BM stem cell niches [79]. In addition, osteoclasts and osteoblasts 
express VEGF [80], so it is reasonable to hypothesize that VEGF concentration is higher 
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near the bones. In this scenario, the paratrabecular region would be the ideal place for 
leukaemia cells to proliferate, thus harbouring a pool of blasts to sustain disease 
progression (Figure 17). 
In summary, our study sheds light on the role of VEGF signalling in the control 
of proliferation of AML cells from monocytic lineage alongside with metabolism. It was 
shown that VEGF regulates the expression of metabolic partners for lactate anabolism 
and catabolism due to the activation of glycolysis in order to supply nucleotide 
synthesis and ultimately cell proliferation. The abrogation of MCT1 function can be a 
way of directly disturbing monocytic AML metabolism and indirectly affecting 
leukaemia progression. 
 
 
Figure 17 - Model of paratrabecular microenvironment as an ideal leukaemia niche for the 
establishment of a pool of blasts to sustain disease progression. Osteoblasts and osteoclasts express 
high levels of VEGF, which is an important homing and proliferation factor for leukaemia blasts. Besides 
the gradient of VEGF produced by osteoblasts and osteoclasts, leukemic blasts are also affected by the 
VEGF express by themselves, autocrine loop. MCT4 is expressed by normal cells, MCT1 by leukemic 
blasts, indicating the existence of a metabolic symbiosis between normal cells (export produced lactate) 
and leukemic blasts (import and consumption of lactate) that will increase leukemic cells fitness.   
 
42 
 
Conclusions 
As mentioned along the present thesis, cancer metabolism is a newly re-
discovered research area, being considered a disease hallmark. Hence, metabolic 
adaptation may be a wealth of elements that despite their physiological and 
pathophysiologycal redundancy can provide new, effective and individual specific 
therapeutic targets. 
The present study shed a light in the role of VEGF in the regulation of lactate 
metabolism in AML. By in vitro assays, it was seen that VEGF and lactate itself 
modulate the expression of MCT1 the main importer of lactate. The higher capacity of 
lactate import is consequently reflected in the metabolic profile. However, the 
mechanism underlying the regulation by VEGF must be disclosed, as listed in future 
perspectives. 
Supporting in vitro evidences, in AML BM samples it was observed that MCT1 is 
expressed in leukaemia cells that are mainly located in paratrabecular region, near the 
bones, where VEGF concentration is higher making this region an ideal place for 
leukaemia cells to proliferate, thus harbouring a pool of blasts to sustain disease 
progression (Figure 17). 
These findings suggest that targeting MCT1 will probably interfere with tumour 
dynamics within BM microenvironment, destabilising leukaemia homeostasis and 
affecting cells survival and disease progression.  
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Future perspectives 
 
This work showed that VEGF have an important role in the control of monocytic 
AML cells proliferation and metabolism but not in the eythroblastic AML cells. It would 
be important to perform the same assays in more AML lineages to understand if VEGF 
importance is singular or common to other AML lineages.  
We also must disclose which VEGF receptor is mediating the influence of VEGF 
in lactate metabolism and cell proliferation by investigating the activation status of 
FLT1 and KDR and the expression and phosphorylation status of the downstream 
effectors of VEGF pathway, by western blot. 
The origin of nucleotides that are produced upon VEGF stimulation in HL60 cell 
line is a crucial research subject, once again trying to find a metabolic track that 
confers cancer growth advantage and simultaneously constitute a new strategy to find 
therapeutic targets. We will test other organic compounds, namely amino acids and 
fatty acids in order to find the carbon source for nucleotides synthesis, in these cells. 
There are evidences that MCT1 levels are increased upon clinical relapse, more 
retrospective data from relapse cases will be included in the study. This link will 
strength the rational that MCT1 is a key element in AML progression. 
 Ultimately, a murine anti-human MCT1 blocking antibody will be produced and 
validated in AML animal models. 
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Appendix I  
Solutions prepared for the experimental work:  
 
Luria-Bertani (LB) medium (Sambrook & Russel, 2001) 
For 1L:  
10g Tryptone (L42, Oxoid)  
5g Yeast extract (403 687, Cultimed)  
10g NaCl (106404, Merck)  
ddH2O to 1L 
 
10X PBS (pH 7.4-7.6) (Sambrook & Russel, 2001) 
For 1L:  
80g NaCl (1.37M) (106404, Merck)  
2g KH2PO4 (14.7mM) (104873, Merck)  
11.1g Na2HPO4 (78.1mM) (S-0876, Sigma)  
2g KCl (26.8mM) (104936, Merck)  
ddH2O to 1L 
 
5X SDS gel loading buffer (Sambrook & Russel, 2001) 
250 mM Tris HCl (pH 6.8) (0.5M 161-0799, Bio-rad)  
10% SDS (V6551, Promega)  
0.5% bromophenol blue 
50% glycerol (1.04094.1000, Merck)  
 
Transfer buffer  
For 5L:  
75g glycine (US16407, USB)  
15g Trizma-base (T-8524, Sigma)  
ddH2O to 4L  
1L Methanol (107018, Merck)  
5mL 10% SDS (V6551, Promega)  
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15% resolving gel and 5% stacking gel for Tris-glycine SDS-Polyacrylamide Gel 
Electrophoresis prepared accordingly to Sambrook & Russel, 2001  
 
PBS with 0.1% (v/v) Tween 20 
For 1L:  
1mL Tween 20 (20605, USB)  
PBS to 1L 
 
PBS with 0.2% (w/v) BSA 
0.4g BSA (A9647, Sigma)  
200 mL PBS 
 
5% (w/v) skimmed milk in PBS 0.1% (v/v) Tween 20 
5g skimmed milk (Molico, Nestlé)  
100 mL PBS 0.1% (v/v) Tween 20 
 
50 μg/mL Propidium Iodide (PI) solution – Cell cycle assay 
For 50 mL:  
1 mL of 2.5 mg/mL PI solution (P4170, Sigma) (prepared in PBS)  
49 mL PBS  
0.1 mg/mL RNase A (Easy spin kit, Citomed)  
0.05% Triton X-100 (T8787, Sigma) 
 
RIPA Buffer 
20mM Tris pH 7,5 
150mM NaCl 
5mM KCl 
5mM MgCl2 
Triton X-100 1% 
Protease inhibitor cocktail tablet 
1mM Orthovanadate 
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Annexin binding buffer  
0.01 M Hepes (pH 7.4) (391333, Millipore)  
0.14 M NaCl (106404, Merck)  
2.5 mM CaCl2 (449709, Sigma)  
 
